Lanasa, Mark C <br/><br/>
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.  [electronic resource] 

 -  Leukemia & lymphoma  Feb 2012 
 - 218-24 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2011.610012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Oligonucleotides--therapeutic use<br/>Prognosis<br/>Risk Factors<br/>Rituximab<br/>Survival Rate<br/>Tumor Suppressor Protein p53--antagonists & inhibitors<br/>Vidarabine--administration & dosage